- Home
- ANAB vs GNK Comparison
ANAB vs GNK Comparison
Compare ANAB & GNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GNK
- Stock Information
- Founded
- ANAB 2005
- GNK 2004
- Country
- ANAB United States
- GNK United States
- Employees
- ANAB N/A
- GNK N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GNK Marine Transportation
- Sector
- ANAB Health Care
- GNK Consumer Discretionary
- Exchange
- ANAB Nasdaq
- GNK Nasdaq
- Market Cap
- ANAB 759.5M
- GNK 707.2M
- IPO Year
- ANAB 2017
- GNK 2005
- Fundamental
- Price
- ANAB $13.04
- GNK $13.91
- Analyst Decision
- ANAB Buy
- GNK Strong Buy
- Analyst Count
- ANAB 11
- GNK 6
- Target Price
- ANAB $42.67
- GNK $24.20
- AVG Volume (30 Days)
- ANAB 775.9K
- GNK 420.0K
- Earning Date
- ANAB 11-05-2024
- GNK 02-19-2025
- Dividend Yield
- ANAB N/A
- GNK 11.34%
- EPS Growth
- ANAB N/A
- GNK 527.82
- EPS
- ANAB N/A
- GNK 1.58
- Revenue
- ANAB $57,172,000.00
- GNK $439,330,000.00
- Revenue This Year
- ANAB $233.68
- GNK $7.51
- Revenue Next Year
- ANAB N/A
- GNK N/A
- P/E Ratio
- ANAB N/A
- GNK $8.78
- Revenue Growth
- ANAB 282.17
- GNK 11.14
- 52 Week Low
- ANAB $13.00
- GNK $13.51
- 52 Week High
- ANAB $41.31
- GNK $23.43
- Technical
- Relative Strength Index (RSI)
- ANAB 27.77
- GNK 28.76
- Support Level
- ANAB $15.11
- GNK $13.51
- Resistance Level
- ANAB $16.74
- GNK $14.17
- Average True Range (ATR)
- ANAB 1.48
- GNK 0.39
- MACD
- ANAB -0.31
- GNK -0.02
- Stochastic Oscillator
- ANAB 0.31
- GNK 19.90
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, the ocean transportation of drybulk cargoes through the ownership and operation of drybulk carrier vessels. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters.